159 related articles for article (PubMed ID: 22982188)
1. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor.
Syed F; Sherris D; Paus R; Varmeh S; Singh S; Pandolfi PP; Bayat A
Am J Pathol; 2012 Nov; 181(5):1642-58. PubMed ID: 22982188
[TBL] [Abstract][Full Text] [Related]
2. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.
Syed F; Sanganee HJ; Singh S; Bahl A; Bayat A
J Invest Dermatol; 2013 May; 133(5):1340-50. PubMed ID: 23303455
[TBL] [Abstract][Full Text] [Related]
3. CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2.
Tu T; Huang J; Lin M; Gao Z; Wu X; Zhang W; Zhou G; Wang W; Liu W
Int J Mol Med; 2019 Nov; 44(5):1789-1800. PubMed ID: 31545402
[TBL] [Abstract][Full Text] [Related]
4. The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation.
Ferguson KT; Torr EE; Bernau K; Leet J; Sherris D; Sandbo N
J Cell Biochem; 2017 Aug; 118(8):2241-2249. PubMed ID: 28078713
[TBL] [Abstract][Full Text] [Related]
5. mTOR as a potential therapeutic target for treatment of keloids and excessive scars.
Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT
Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482
[TBL] [Abstract][Full Text] [Related]
6. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract][Full Text] [Related]
7. [In vitro study of effects and mechanism of rapamycin-induced autophagy in keloid fibroblasts].
Gao J; Jiao H; Cao R; Yang Z; Sun X; Zhuang Q; Xiao Z; Yan Z
Zhonghua Zheng Xing Wai Ke Za Zhi; 2016 May; 32(3):208-14. PubMed ID: 30044067
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes.
Chen J; Liu K; Liu Y; Wang X; Zhang Z
Exp Dermatol; 2019 Mar; 28(3):270-275. PubMed ID: 30650200
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
Wang W; Qu M; Xu L; Wu X; Gao Z; Gu T; Zhang W; Ding X; Liu W; Chen YL
J Mol Med (Berl); 2016 Oct; 94(10):1181-1194. PubMed ID: 27339758
[TBL] [Abstract][Full Text] [Related]
10. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway.
Park G; Yoon BS; Moon JH; Kim B; Jun EK; Oh S; Kim H; Song HJ; Noh JY; Oh C; You S
J Invest Dermatol; 2008 Oct; 128(10):2429-41. PubMed ID: 18463684
[TBL] [Abstract][Full Text] [Related]
11. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.
Yan J; Zhou H; Kong L; Zhang J; Zhao Q; Li Y
Cancer Chemother Pharmacol; 2013 Oct; 72(4):799-808. PubMed ID: 23934262
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization.
Zhou BY; Wang WB; Wu XL; Zhang WJ; Zhou GD; Gao Z; Liu W
Acta Pharmacol Sin; 2020 Sep; 41(9):1234-1245. PubMed ID: 32327724
[TBL] [Abstract][Full Text] [Related]
13. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
16. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
[TBL] [Abstract][Full Text] [Related]
17. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
18. Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes.
Wang M; Chen L; Huang W; Jin M; Wang Q; Gao Z; Jin Z
Int J Nanomedicine; 2019; 14():1385-1400. PubMed ID: 30863067
[TBL] [Abstract][Full Text] [Related]
19. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
20. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
